The antibody-drug conjugate sofetabart mipitecan showed efficacy and safety, leading to selection of a phase 3 dose for the FRAmework-01 trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
2
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
3
Claudin 6–Targeted ADC Shows Activity in Germ Cell Tumors
4
Olomorasib Combo Shows Manageable Liver Toxicity in KRAS G12C-Mutant NSCLC
5